期刊
BLOOD
卷 121, 期 16, 页码 3284-3288出版社
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2012-11-469627
关键词
-
类别
资金
- Deutsche Jose-Carreras Leukamiestiftung e.V. Projects [R02/18, R05/02]
- Else Kroner Fresenius Stiftung (Else Kroner Forschungskolleg Ulm)
- CLL Global Research Foundation (Alliance)
- Virtual Helmholtz Institute [VH-VI-404, TP2]
- DFG [SFB 1074]
The purpose of this analysis was to provide 6-year follow-up of the CLL3X trial, which studied reduced-intensity allogeneic hematopoietic stem cell transplantation (HSCT) in patients with poor-risk chronic lymphocytic leukemia (CLL), and to investigate the effect of TP53, SF3B1, and NOTCH1 mutations on HSCT outcome. For 90 allografted patients, 6-year overall survival (OS) was 58% and 6-year event-free survival (EFS) was 38%. TP53, SF3B1, and NOTCH1 mutations were found in 30%, 26%, and 14% of the trial population, respectively. By univariate and multivariate analyses, the mutational status of the TP53, SF3B1, and NOTCH1 genes had no significant effect on OS and EFS. Studies of minimal residual disease confirmed durability of CLL eradication in mutated patients. We conclude that HSCT can provide long-term disease control in patients with poor-risk CLL independent of the presence of TP53, SF3B1, and NOTCH1 mutations. The trial has been registered at the US National Cancer Institute as #EU-20554, NCT00281983.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据